Biopharma industry pushing for changes to Biosecure Act

With Congress on track to pass legislation based on the Biosecure Act in December, the biopharma industry is scrambling to collect evidence about the impacts of a forced decoupling from Chinese contract development and manufacturing organizations and to use the information to convince lawmakers to modify the bill.

A May 15 House Oversight and Accountability Committee hearing that will consider proposals to modify the Biosecure Act (H.R. 7085) will provide an early readout on the efficacy of the industry’s lobbying on the bill...